Transmedics Group Inc [TMDX] stock is trading at $118.06, up 2.50%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The TMDX shares have gain 2.76% over the last week, with a monthly amount glided 9.03%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Transmedics Group Inc [NASDAQ: TMDX] stock has seen the most recent analyst activity on September 16, 2025, when Evercore ISI initiated its Outperform rating and assigned the stock a price target of $155. Previously, Stifel started tracking the stock with Hold rating on September 04, 2025, and set its price target to $115. On December 17, 2024, downgrade downgraded it’s rating to Neutral and revised its price target to $75 on the stock. Needham downgraded its rating to a Hold. Oppenheimer reiterated its recommendation of a Outperform and reduced its price target to $125 on October 29, 2024. Needham reiterated a Buy rating for this stock on October 29, 2024, and downed its price target to $109. In a note dated September 24, 2024, Robert W. Baird initiated an Outperform rating and provided a target price of $200 on this stock.
Transmedics Group Inc [TMDX] stock has fluctuated between $55.00 and $145.50 over the past year. Currently, Wall Street analysts expect the stock to reach $155 within the next 12 months. Transmedics Group Inc [NASDAQ: TMDX] shares were valued at $118.06 at the most recent close of the market. An investor can expect a potential return of 31.29% based on the average TMDX price forecast.
Analyzing the TMDX fundamentals
Transmedics Group Inc [NASDAQ:TMDX] reported sales of 531.29M for the trailing twelve months, which represents a growth of 37.68%. Gross Profit Margin for this corporation currently stands at 0.6% with Operating Profit Margin at 0.14%, Pretax Profit Margin comes in at 0.14%, and Net Profit Margin reading is 0.13%. To continue investigating profitability, this company’s Return on Assets is posted at 0.08, Equity is 0.28 and Total Capital is 0.09. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.63.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 114.97 points at the first support level, and at 111.88 for the second support level. However, for the 1st resistance point, the stock is sitting at 120.22, and for the 2nd resistance point, it is at 122.38.
Ratios To Look Out For
For context, Transmedics Group Inc’s Current Ratio is 9.86. Also, the Quick Ratio is 9.17, while the Cash Ratio stands at 7.07. Considering the valuation of this stock, the price to sales ratio is 7.58, the price to book ratio is 12.63 and price to earnings (TTM) ratio is 61.05.
Transactions by insiders
Recent insider trading involved Hassanein Waleed H, President & CEO, that happened on Aug 06 ’25 when 8400.0 shares were purchased. President & CEO, Hassanein Waleed H completed a deal on Aug 07 ’25 to buy 8475.0 shares. Meanwhile, Director Basile Edward M sold 4143.0 shares on Aug 04 ’25.
